Despite today's firing of CEO, Martin Shkreli, KaloBios Pharma (NASDAQ: KBIO) shares remain halted on the NASDAQ exchange with a T12 halt code - 'Additional Information Requested by NASDAQ.'

Shares have been halted since 6:48AM on Thursday 12/17 after news broke that Mr. Shkreli was arrested for securities fraud related to his past dealings with investors of his hedge fund and as the CEO of Retrophin (NASDAQ: RTRX).

Shares were trading down 50% from the 12/16 close of $23.59 before the halt last Thursday. It is expected that shares could trade in the low single digits once trading resumes. The stock was at $0.90 before Mr. Shkreli's involvement. Shkreli orchestrated a short squeeze in the stock, in part by pulling the borrow on stock he owned, pushing shares to as high as $45.82.

A NASDAQ spokesperson wouldn't address questions from StreetInsider related to if today's news addresses the information request, but it may be safe to say that it doesn't given the code wasn't changed following today's release.